I now have comprehensive data from multiple authoritative textbooks. Here is the full answer:
Serial measurements help distinguish these from ACS, which typically shows a dynamic rise-and-fall pattern of greater magnitude.
-
ACS vs. non-ACS troponin elevation: ACS typically shows a dynamic rise-and-fall of greater magnitude; non-ACS causes tend to show a flat or plateau pattern on serial testing. - Fuster and Hurst's The Heart, 15th Ed.
-
Highly sensitive troponin (hsTn) assays have increased the detection of non-ACS elevations significantly - up to 50% of all in-hospital troponin rises may not be due to ACS.
-
Renal failure is a special case: do NOT dismiss troponin elevation as "just CKD" - it still predicts adverse cardiovascular outcomes and NSTE-ACS must be excluded by serial testing and clinical context.
-
Pulmonary embolism deserves particular attention as it can closely mimic ACS clinically (chest pain, dyspnea, ST-T changes, troponin elevation).
-
Treatment should focus on the underlying disease when a non-ACS cause is identified. Echocardiography is useful given the frequent association of chronic troponin elevation with structural cardiac abnormalities.
A recent 2025 review (
Savic et al., Int J Mol Sci, PMID 41373801) confirms that elevated troponin in non-cardiac conditions is an independent predictor of cardiovascular and overall mortality, and treatment of the underlying condition is the primary goal.